Company / Shareholders' Equity
ADMA Biologics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$477.3M
FY2025
5-year range
$88.2M / $477.3M
FY2021-FY2025
Trend
+36.8%
vs FY2024
Sector context
#98 of 213
Health Care
What the data says
At $477M, ADMA Biologics, Inc.'s shareholders' equity ranks #98 of 213 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $88M in FY2022 to $477M in FY2025.
Based on SEC 10-K filings.
$477M in FY2025 with a 5-year CAGR of +40.2%.
Improved from $135M to $477M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +75.5%
- 5-Year CAGR
- +40.2%
- 10-Year CAGR
- -
Sector benchmark
#98 of 213 in Health CareTop 46% of 213This company $477.3M Sector average $2.5B
▼
-81.3% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +40.2%, indicating consistent growth.
- In FY2025, shareholders' equity increased 36.8% year-over-year.
- Ranks #98 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $477.3M | +36.8% |
| FY2024 | $349.0M | +158.1% |
| FY2023 | $135.2M | +53.2% |
| FY2022 | $88.2M | -37.5% |
| FY2021 | $141.2M | +60.0% |
| FY2020 | $88.2M | +236.9% |
| FY2019 | $26.2M | +32.5% |
| FY2018 | $19.8M | +543.6% |
| FY2017 | -$4.5M | +0.0% |
| FY2016 | -$4.5M | -174.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026